As Richard Beddie observed: At Bay Surgery in Tauranga, we encourage patients to take a holistic view: Get the tools you need to lose weight, yesbut do so in a way that builds and protects strength, vitality and a healthier future
Furthermore, these reports did not well characterize the unique dermoscopic features of LMM, because it had encompassed entire pigmented lesions on mucocutaneous junction and mucous membrane3, 5, 6

Why Alcohol is Tricky on GLP-1s GLP-1s slow gastric emptyingalcohol may hit you harder and faster Alcohol on an empty stomach is worse on GLP-1s Many users report significantly worsened nausea Alcohol lowers inhibitions (may lead to poor food choices) Empty calories without nutrition If You Choose to Drink Stick to these guidelines: Limit to 1 drink maximum Always drink with food (never on empty stomach) Choose lower-calorie options: Wine (5 oz), light beer, spirits with soda water and lime Avoid: Sugary cocktails, margaritas, pia coladas, multiple drinks Drink slowly (sip over 45-60 minutes) Hydrate: Drink water before, during, and after Monitor your response (if you feel worse, skip alcohol entirely going forward) Best Choices if Drinking Dry wine (red or white): ~120 calories per 5 oz Light beer: ~100 calories per 12 oz Vodka/gin + soda water + lime: ~100 calories Champagne/prosecco: ~90 calories per 4 oz Social Pressure to Drink If you prefer to skip alcohol but feel social pressure: Order sparkling water with lime (looks like a cocktail) Say "I'm taking a break from alcohol" Say "Mixing badly with medication I'm on" Hold a non-alcoholic drink so people don't keep offering Real friends respect your choices

It is with deep sadness that we share the news of the passing of Joel Habener, MD, an extraordinary physician-scientist, mentor, and beloved member of our Mass General Brigham community whose discoveries transformed the field of endocrinology and the care of millions of patients worldwide
Using GLP-1 RAs alongside other glucose-lowering or cardiovascular medications can significantly enhance therapeutic outcomes, reduce side effects, and better address the diverse needs of different patients
MEDI0382, a GLP-1 and Glucagon Receptor Dual Agonist, in Obese or Overweight Patients With Type 2 Diabetes: A Randomised, Controlled, Double-Blind, Ascending Dose and Phase 2a Study